10 September 2019 in Neurology
Objective To examine whether plasma neurofilament light chain (NfL) levels were associated with motor and cognitive progression in Parkinson disease (PD). Methods This prospective follow-up study enrolled 178 participants, including 116 with PD, 22 with multiple system atrophy (MSA), and 40 healthy controls. We measured plasma NfL levels with electrochemiluminescence immunoassay. Patients with PD received evaluations of motor and cognition at baseline and at a mean follow-up interval of 3 years. Changes in the Unified Parkinson9s Disease Rating Scale (UPDRS) part III motor score and Mini-Mental State Examination score were used to assess motor and cognition progression. Results Plasma NfL levels were significantly higher in the MSA group than in the PD and healthy groups (35.8 ± 6.2, 17.6 ± 2.8, and 10.6 ± 2.3 pg/mL, respectively, p < 0.001). In the PD group, NfL levels were significantly elevated in patients with advanced Hoehn-Yahr stage and patients with dementia (p < 0.001). NfL levels were modestly correlated with UPDRS part III scores (r = 0.42, 95% confidence interval 0.46–0.56, p < 0.001). After a mean follow-up of 3.4 ± 1.2 years, a Cox regression analysis adjusted for age, sex, disease duration, and baseline motor or cognitive status showed that higher baseline NfL levels were associated with higher risks for either motor or cognition progression (p = 0.029 and p = 0.015, respectively). Conclusions Plasma NfL levels correlated with disease severity and progression in terms of both motor and cognitive functions in PD. Classification of evidence This study provides Class III evidence that plasma NfL level distinguishes PD from MSA and is a surrogate biomarker for PD progression.
27 January 2020 in Brain and Behavior
Introduction: Frontal variant of Alzheimer's disease (fvAD) is a rare nonamnestic syndrome of Alzheimer's disease (AD). Differentiating it from behavior variant of frontotemporal dementia (bvFTD), which has implications for treatment responses and prognosis, remains a clinical challenge.Methods: Molecular neuroimaging and biofluid markers were performed for the index patient for accurate premortem diagnosis of fvAD. The clinical, neuroimaging, and biofluid characteristics of the patient were compared to those reported in previous studies of fvAD from 1999 to 2019.Results: A 66‐year‐old man presented with progressive executive dysfunction, personality and behavioral changes, and memory decline since age 59. He had no family history of neurodegenerative disorders. A stimulus‐sensitive myoclonus was noted over his left upper extremity. Neuropsychological assessment revealed moderate dementia with a Mini‐Mental State Exam score of 10/30 and compromised executive and memory performance. Brain imaging showed asymmetrical atrophy and hypometabolism over the right frontal and temporal areas, mimicking bvFTD. However, we observed increased tau depositions based on 18F‐labeled T807 Tau PET in these areas and diffusely increased amyloid deposition based on 11C‐labeled Pittsburgh compound B positron emission tomography (PET). Plasma biomarker measures indicated an AD profile with increased Aβ1‐42 (18.66 pg/ml; cutoff: 16.42 pg/ml), Aβ1‐42/Aβ1‐40 ratio (0.45; cutoff: 0.30), total tau (29.78 pg/ml; cutoff: 23.89 pg/ml), and phosphorylated tau (4.11 pg/ml; cutoff: 3.08 pg/ml). These results supported a diagnosis of fvAD.Conclusions: Our results with asymmetrical presentations extend current knowledge about this rare AD variant. Application of biofluid and molecular imaging markers could assist in early, accurate diagnosis.
8 December 2024 in Journal of Parkinson’s Disease
Background: 18 F-florzolotau positron emission tomography (PET) assists in the in vivo diagnosis of progressive supranuclear palsy (PSP). Objective: We aimed to investigate the relationship between 18 F-florzolotau uptake and clinical severity, structural volume changes, and plasma markers in four-repeat tauopathies. Methods: A total of 80 participants were recruited: 35 with PSP (11 with PSP-Richardson syndrome and 24 with PSP non-Richardson syndrome), 9 with corticobasal syndrome (CBS), 10 with Alzheimer's disease (AD), 8 with Parkinson's disease, and 18 controls. All participants underwent 18 F-florzolotau PET, brain magnetic resonance imaging (MRI), and plasma biomarker investigation (total and phosphorylated tau [pTau181], neurofilament light chain, and glial fibrillary acidic protein [GFAP]). Results: 18 F-Florzolotau uptake was significantly higher in the subcortical regions of the pallidum, subthalamic nucleus (STN), midbrain, red nucleus, and raphe nucleus in PSP patients compared to the other groups (all p < 0.01). Subcortical tau tracer retention assisted in distinguishing PSP and CBS from controls (AUC = 0.836, p < 0.001). Tau tracer retention could differentiate PSP and CBS from AD in cortical ( p < 0.001) and subcortical regions ( p = 0.028). The motor severity of PSP positively correlated with tau burden in STN ( p = 0.044) and substantia nigra ( p = 0.035). Tau tracer uptake was associated with cortical volume changes in CBS ( p = 0.031), PSP non-Richardson syndrome ( p = 0.003), and AD ( p = 0.044). Cortical tau retention correlated with plasma levels of GFAP ( p = 0.001) and pTau181 ( p = 0.036). Conclusions: Subcortical 18 F-Florzolotau uptake assist the diagnosis of 4R tauopathy parkinsonism. Additionally, regional tau burden contributes to structural brain volume changes and correlates with plasma levels of GFAP and pTau181.
5 December 2025 in Journal of the Formosan Medical Association
Parkinson's disease (PD) is the fastest-growing neurological disorder worldwide, largely driven by the aging global population, and poses major challenges in clinical management due to progressive disability, the emergence of symptoms insufficiently controlled by current therapies, and treatment-related complications. In this Review, we revisit the definition of PD beyond its clinical manifestations, emphasizing the evolving framework of biological classification. We examine advances in genetics and explore the structural and physiological roles of α-synuclein, with particular attention to post-translational modifications, their contributions to neurodegeneration, and the existence of disease-specific α-synuclein strains that underlie pathological propagation. We highlight recent progress in diagnostic technologies, including seed amplification assays and PET tracers for pathological α-synuclein detection, as well as updates in MRI-based imaging and digital biomarkers to support early detection and differentiation of PD from atypical parkinsonian syndromes. Finally, we review the current therapeutic landscape, encompassing pharmacological therapies, surgical approaches such as deep brain stimulation, and emerging neuromodulation strategies, including adaptive deep brain stimulation, transcranial magnetic stimulation, and focused ultrasound. Together, these strategies will bridge the gap to transform both the understanding and clinical care of PD in the coming decade.
15 January 2025 in Journal of the Formosan Medical Association
Controlling hypertension has become an important issue in the elderly population in whom neurological comorbidities are highly prevalent. Most of the large-scale trials focusing on hypertension management in older populations have excluded patients with comorbid neurological disorders. However, this population requires special considerations, as the benefits of antihypertensive agents are mostly uncertain and there is a higher risk of adverse events. In this review article, we discuss current evidence regarding the management of elderly patients with hypertension and common neurological disorders, including stroke and neurodegenerative diseases. In elderly patient with a history of stroke, the blood pressure management strategy is generally similar to that for young patients, however the benefits of stroke prevention from blood pressure control are less significant. For patients with neurodegenerative disorders such as cognitive dysfunction and Parkinson's disease, achieving adequate blood pressure control may be beneficial in reducing cardiovascular risks, although the higher risk of adverse events from antihypertensive treatment may offset some of these benefits. Special considerations for factors such as orthostatic hypotension, risk of falls, polypharmacy, and significant drug-drug interactions are required but frequently neglected in clinical practice. More efforts are warranted to determine the optimal treatment strategy for elderly populations with neurological disorders.
5 September 2025 in Annals of Clinical and Translational Neurology
Objective: Neuroinflammation driven by extracellular copper contributes to neuronal damage in Wilson's disease (WD). This study investigated the relationship between brain metal burden and peripheral neuroinflammation markers in WD. Methods: We conducted a cross‐sectional study involving 89 participants, including patients with WD ( n = 63), asymptomatic ATP7B heterozygous carriers ( n = 12), and age/sex‐matched controls ( n = 14). Brain metal burden was assessed using quantitative susceptibility mapping (QSM) MRI. Plasma glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels were measured. Clinical severity was evaluated using the mini–Unified Wilson's Disease Rating Scale (UWDRS) and Montreal Cognitive Assessment (MoCA). The influence of copper chelation treatment on biomarker correlations was also examined. Results: Patients with WD had a significantly higher level of GFAP ( p = 0.02) and brain metal burden ( p < 0.01) than the control group. Plasma NfL levels were marginally elevated in the WD group ( p = 0.07). Notably, elevated plasma GFAP levels were significantly associated with higher UWDRS scores ( r = 0.35, p < 0.01) and lower MoCA scores ( r = −0.36, p < 0.01). The NfL levels were also correlated with UWDRS ( r = 0.58, p < 0.01) and marginally correlated with MoCA ( r = −0.32, p = 0.02). The brain magnetic susceptibility value was positively correlated with increased plasma GFAP level, particularly in the putamen ( p < 0.001), which was more prominent in WD patients without chelating agent treatment ( r = 0.58, p < 0.001). Interpretations: Plasma GFAP levels reflect both clinical severity and brain metal accumulation in WD, with this association influenced by copper chelation therapy.